Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio company Polyheal Ltd. has presented good results in the clinical trial of its Polyheal-1 treatment for chronic wounds. The company earlier reported good preliminary results.

Polyheal said that the results would help it in ongoing negotiations on business collaboration for the product with pharmaceutical companies.

Polyheal has already obtained EU CE Mark certification for Polyheal-1. The trial will be a basis for additional trials in order to obtain US Food and Drug Administration (FDA) certification.

The trial included 66 patients with chronic wounds. Half the patients received Polyheal-1 and half received a conventional treatment, as the control group. The wounds in 65% of the patients who received Polyheal-1 were covered by granular tissue, the first stage in the healing process, compared with 19% of the patients who received the conventional treatment. The area of the wound in the patients receiving Polyheal-1 was reduced by 40%, compared with a 15% reduction in the control group. Polyheal-1 completely closed twice as many wounds as the conventional treatment.

Polyheal CEO Jordan Rubinson said, "We achieved our primary target of the work plan: clear proof that the product is effective. This achievement will speed up distribution and sales of the product in Europe and the regulatory process in the US."

Published by Globes [online], Israel business news - www.globes-online.com - on December 8, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009